20 percent more patients were treated with proton therapy in 2019

An individual eye shield is made for each patient to protect the surrounding tissue from the proton beam.

An individual eye shield is made for each patient to protect the surrounding tissue from the proton beam. © HZB

Number of patients who received the proton therapy offered jointly by Charité and HZB.

Number of patients who received the proton therapy offered jointly by Charité and HZB. © HZB/J. Politt

For more than 20 years, Charité - Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have jointly offered the irradiation of eye tumors with protons. In 2019, more patients were treated in Berlin-Wannsee than ever before. 276 patients - 20 percent more than in the previous year - underwent proton therapy. The treatment is specialized in choroidal melanomas of the eye. The proton accelerator at HZB is the only treatment facility for this disease in Germany. 

500 to 600 people in Germany are affected by a malignant choroidal melanoma every year. In 97 percent of cases, the tumour can be completely destroyed by irradiation with protons. In most cases, not only the eye but also the vision can be maintained to a satisfactory degree. "The energy of the proton beam can be adjusted in such a way that practically only the tumor receives the radiation. Since the protons have a straight trajectory, the lateral scattering is much less than with X-rays," explains Dr. Jens Heufelder, the senior medical physicist at Charité - Universitätsmedizin Berlin. The protons effectively destroy the tumor, while the surrounding healthy tissue is largely spared.

To cope with the increase in patients in 2019, treatment operations at the proton accelerator have been extended to 12 hours. Approximately 45 percent of the patients came from the Berlin-Brandenburg region, the other patients came from other German states and other European countries (approximately 8 percent). The youngest patient who received proton therapy at HZB in 2019 was 8 years old, the oldest patient 96 years old. The average age was 61 years.

Since 1998, more than 3,700 patients have been treated with protons from the HZB accelerator. "The success of proton therapy is based on the collaboration between ophthalmologists, medical physicists and accelerator experts. As a result, the therapy has been continuously improved for the benefit of patients over the past few years", explains Prof. Dr. Andrea Denker, head of proton therapy at HZB. 

(sz)

  • Copy link

You might also be interested in

  • Electrocatalysts: New model for charge separation at the solid-liquid interface
    Science Highlight
    16.04.2026
    Electrocatalysts: New model for charge separation at the solid-liquid interface
    Hydrogen is at the heart of the transition to carbon neutrality, as both an energy carrier and a reagent for green chemistry. However, large-scale production of hydrogen via electrolysis, as well as the production of many other chemical products, requires significantly cheaper and more efficient catalysts. A precise understanding of the electrochemical processes that take place at the interface between the solid catalyst and the liquid medium is highly useful for developing better electrocatalysts. In the journal Nature Communications, an European team has now presented a powerful model that determines charge separation at the interface, the formation of the electric double layer and local electric potential variations, and the resulting influence on the catalytic activity.
  • Theory meets practice – We’re heading back to HTW Berlin!
    News
    07.04.2026
    Theory meets practice – We’re heading back to HTW Berlin!
    The HZB’s BIPV consultancy office (BAIP) is once again coordinating and delivering the lecture series “Building-Integrated Photovoltaics”.
  • AI-driven Catalyst Discovery: €30 million funding for German consortium
    News
    30.03.2026
    AI-driven Catalyst Discovery: €30 million funding for German consortium
    Six partners from research and industry, including Helmholtz-Zentrum Berlin (HZB), the Fritz-Haber-Institute of the Max Planck Society (FHI), BASF, Dunia Innovations, Siemens Energy, and the Technical University Berlin are launching a joint project to accelerate the catalyst discovery. The German Federal Ministry for Science, Technology and Space (BMFTR) is providing €30 million in funding for ASCEND (Accelerated Solutions for Catalysis using Emerging Nanotechnology and Digital Innovation). The research initiative targets the defossilisation of energy-intensive industries while safeguarding industrial competitiveness, with a focus on the chemical sector. The five-year project will start on 1st April 2026.